478 related articles for article (PubMed ID: 12597346)
1. Management of clinical stage I nonseminomatous germ-cell testis tumors.
Flechon A; Droz JP
Expert Rev Anticancer Ther; 2003 Feb; 3(1):21-30. PubMed ID: 12597346
[TBL] [Abstract][Full Text] [Related]
2. The management of stage I nonseminomatous testicular germ cell tumors.
Pectasides D; Farmakis D; Pectasides M
Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
[TBL] [Abstract][Full Text] [Related]
3. [Management of localized germ-cell tumours of the testis].
Loriot Y; Fizazi K
Rev Prat; 2007 Feb; 57(4):379-84. PubMed ID: 17455739
[TBL] [Abstract][Full Text] [Related]
4. Current management of stage I testicular non-seminomatous germ cell tumours.
Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
[TBL] [Abstract][Full Text] [Related]
5. Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
Stephenson AJ; Aprikian AG; Gilligan TD; Oldenburg J; Powles T; Toner GC; Waters WB
Urology; 2011 Oct; 78(4 Suppl):S444-55. PubMed ID: 21986224
[TBL] [Abstract][Full Text] [Related]
6. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment in the management of testis-confined germ cell tumours after orchidectomy.
Sava T; Consoli F; Santo A; Cetto GL
BJU Int; 2008 Jan; 101(2):155-9. PubMed ID: 17662077
[TBL] [Abstract][Full Text] [Related]
8. Management of clinical stage I nonseminomatous germ cell testicular cancer.
Choueiri TK; Stephenson AJ; Gilligan T; Klein EA
Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis.
Sogani PC
Urol Clin North Am; 1991 Aug; 18(3):561-73. PubMed ID: 1652171
[TBL] [Abstract][Full Text] [Related]
10. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
Yoon GH; Stein JP; Skinner DG
Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
[TBL] [Abstract][Full Text] [Related]
11. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors.
Kondagunta GV; Motzer RJ
Urol Clin North Am; 2007 May; 34(2):179-85; abstract ix. PubMed ID: 17484923
[TBL] [Abstract][Full Text] [Related]
13. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
14. Surveillance alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis (NSGCT).
Sogani PC; Fair WR
Semin Urol; 1988 Feb; 6(1):53-6. PubMed ID: 2838876
[No Abstract] [Full Text] [Related]
15. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence.
Nicolai N; Miceli R; Necchi A; Biasoni D; Catanzaro M; Milani A; Piva L; Pizzocaro G; Stagni S; Torelli T; Salvioni R
Eur Urol; 2010 Dec; 58(6):912-8. PubMed ID: 20817343
[TBL] [Abstract][Full Text] [Related]
16. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
17. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
18. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
19. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
Williams SB; Steele GS; Richie JP
J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
